An interventional study of Delipid Extracorporeal Lipoprotein filter from Plasma in Ischemic Stroke, sponsored by General Hospital of Shenyang Military Region. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-15.
Sponsored by General Hospital of Shenyang Military Region · Not applicable, Interventional, and Treatment
Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) has been found to improve neurological function and life ability of AIS patients and approved for the treatment of AIS by China Food and Drug Administration (CFDA). Our recent study imply that the neuroprotective effect of DELP involved multiple neuroprotective mechanism such as anti-inflammation, free radical scavenging, and decreasing MMP-9. Based on the multiple mechanisms, DELP was used to investigate the effect on acute ischemic stroke receiving endovascular treatment.
7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.
This study's enrollment of 60 is above the median of 50 across 5,369 interventional studies indexed under Stroke.
Browse Stroke studies →General Hospital of Shenyang Military Region is the lead sponsor of 78 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) is a non-pharmacological therapy for acute stroke, which is approved by China Food and Drug Administration
Device: Delipid Extracorporeal Lipoprotein filter from Plasma
As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke
Proportion of patients with modified Rankin Score 0 to 2
Time frame: Day 90
Proportion of patients with modified Rankin Score 0 to 1
Time frame: Day 90
Changes in national institutes of health stroke scale (NIHSS)
NIHSS ranges from 0-42, and the decrease in NIHSS means the improvement of neurological deficit.
Time frame: 48 hours
Changes in national institutes of health stroke scale (NIHSS)
NIHSS ranges from 0-42, and the decrease in NIHSS means the improvement of neurological deficit.
Time frame: 7 days
Changes in cerebral infarct volume
Time frame: 48 hours
the occurence of stroke or other cardiovascular events
Time frame: Day 90
the occurence of infections post stroke
Time frame: Day 14
Proportion of symptomatic intracranial hemorrhage (sICH)
sICH was defined as 4 or more increase in NIHSS caused by hemorrhage
Time frame: 48 hours
Proportion of intraparenchymal hemorrhage (PH1 and PH2)
Time frame: 48 hours
the occurence of death due to any cause
Time frame: Day 90
Plan to share: Yes — IPD will be shared in request after the trial finish and will include study protocol, statistical analysis plan.
Supporting information: Study protocol, Sap, Icf, Csr
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
General Hospital of Shenyang Military Region